科源制药
(301281)
| 流通市值：43.37亿 | | | 总市值：43.37亿 |
| 流通股本：1.08亿 | | | 总股本：1.08亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 165,813,255.39 | 171,685,689.31 | 363,604,662.98 | 359,077,870.81 |
| 交易性金融资产 | 170,802,838.14 | 70,163,972.6 | - | - |
| 应收票据及应收账款 | 261,959,545.4 | 226,831,614.7 | 187,052,979.87 | 105,657,550.41 |
| 其中：应收票据 | 15,773,147.15 | 15,905,577.09 | 12,234,886.81 | 9,565,437.94 |
| 应收账款 | 246,186,398.25 | 210,926,037.61 | 174,818,093.06 | 96,092,112.47 |
| 应收款项融资 | 12,784,323.17 | 27,980,743.36 | 11,078,029.99 | 12,316,963.95 |
| 预付款项 | 32,043,354.89 | 25,957,804.21 | 13,882,161.55 | 11,199,029.82 |
| 其他应收款合计 | 2,727,329.35 | 12,856,536.98 | 13,347,822.93 | 12,319,927.45 |
| 存货 | 127,476,900.94 | 127,444,443.29 | 141,478,364.21 | 147,446,770.78 |
| 合同资产 | - | 0 | - | - |
| 其他流动资产 | 1,851,434.63 | 101,380,365.19 | 1,128,482.96 | 4,372,666.65 |
| 流动资产合计 | 775,458,981.91 | 764,301,169.64 | 731,572,504.49 | 652,390,779.87 |
| 非流动资产: | | | | |
| 长期股权投资 | 209,948,873.66 | 196,934,775.76 | 188,266,560.06 | 188,866,560 |
| 其他权益工具投资 | 27,651,414.32 | 2,651,414.32 | 2,651,414.32 | 2,651,414.32 |
| 固定资产 | 366,716,215.3 | 357,207,901.87 | 278,091,456.99 | 289,198,787.79 |
| 在建工程 | 330,367,771.48 | 334,235,262.92 | 405,240,027.95 | 390,164,728.76 |
| 无形资产 | 197,532,334.56 | 194,552,649.1 | 112,942,744.82 | 112,740,739.21 |
| 开发支出 | 13,426,415.1 | 810,000 | 810,000 | 2,619,433.96 |
| 商誉 | 1,025,455.1 | 1,025,455.1 | 1,025,455.1 | 1,025,455.1 |
| 长期待摊费用 | 1,664,518.24 | 1,662,084.84 | 1,795,880.84 | 965,960.88 |
| 递延所得税资产 | 5,041,911.14 | 5,029,704.01 | 4,343,201.19 | 4,261,719.99 |
| 其他非流动资产 | 39,774,373.24 | 52,606,855.09 | 64,056,740.43 | 42,779,449.9 |
| 非流动资产合计 | 1,193,149,282.14 | 1,146,716,103.01 | 1,059,223,481.7 | 1,035,274,249.91 |
| 资产总计 | 1,968,608,264.05 | 1,911,017,272.65 | 1,790,795,986.19 | 1,687,665,029.78 |
| 流动负债: | | | | |
| 短期借款 | 99,767,364.5 | 82,664,778.88 | 39,435,290.37 | - |
| 应付票据及应付账款 | 139,675,158.82 | 140,996,743.21 | 102,937,727.57 | 105,653,470.23 |
| 其中：应付票据 | - | - | 8,950,237.5 | 9,450,237.5 |
| 应付账款 | 139,675,158.82 | 140,996,743.21 | 93,987,490.07 | 96,203,232.73 |
| 合同负债 | 13,950,098.6 | 5,907,569.41 | 6,414,213.67 | 6,771,423.92 |
| 应付职工薪酬 | 13,576,706.53 | 12,867,340.74 | 12,911,087.8 | 12,428,932.49 |
| 应交税费 | 8,163,005.39 | 15,140,225.15 | 9,348,620.09 | 1,444,516.08 |
| 其他应付款合计 | 71,252,872.9 | 69,361,711.48 | 58,548,137.36 | 41,603,268.97 |
| 其他流动负债 | 9,650,790.11 | 5,056,238.67 | 10,079,535.95 | 8,085,680.35 |
| 流动负债合计 | 356,035,996.85 | 331,994,607.54 | 239,674,612.81 | 175,987,292.04 |
| 非流动负债: | | | | |
| 长期借款 | 118,778,609.34 | 120,385,019.34 | 117,147,993.16 | 112,344,762.56 |
| 预计负债 | 338,553.43 | 338,553.43 | 16,445,553.43 | 16,445,553.43 |
| 递延收益 | 12,828,378.21 | 11,638,215.57 | 7,862,108.6 | 8,412,118.31 |
| 递延所得税负债 | 18,554,583.61 | 16,720,848.89 | 16,270,860.89 | 18,293,556.62 |
| 非流动负债合计 | 150,500,124.59 | 149,082,637.23 | 157,726,516.08 | 155,495,990.92 |
| 负债合计 | 506,536,121.44 | 481,077,244.77 | 397,401,128.89 | 331,483,282.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 108,290,000 | 108,290,000 | 108,290,000 | 108,290,000 |
| 资本公积 | 929,042,926.08 | 919,917,818.88 | 912,796,880.18 | 907,682,874.3 |
| 专项储备 | 7,524,848.86 | 6,884,757.69 | 5,980,570.5 | 4,417,537.9 |
| 盈余公积 | 51,647,652.61 | 51,647,652.61 | 51,647,652.61 | 51,647,652.61 |
| 未分配利润 | 363,441,230.31 | 342,789,782.05 | 313,585,641.02 | 283,512,215.79 |
| 归属于母公司股东权益合计 | 1,459,946,657.86 | 1,429,530,011.23 | 1,392,300,744.31 | 1,355,550,280.6 |
| 少数股东权益 | 2,125,484.75 | 410,016.65 | 1,094,112.99 | 631,466.22 |
| 股东权益合计 | 1,462,072,142.61 | 1,429,940,027.88 | 1,393,394,857.3 | 1,356,181,746.82 |
| 负债和股东权益合计 | 1,968,608,264.05 | 1,911,017,272.65 | 1,790,795,986.19 | 1,687,665,029.78 |
| 公告日期 | 2026-10-26 | 2026-08-27 | 2026-04-24 | 2026-04-16 |
| 审计意见(境内) | | | | 标准无保留意见 |